Liège, Belgium – 1 November 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the…Original Article
Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic IV in Post-Operative Pain
